soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral semaglutide found to lower

Its appropriate for single-use preparations, where the solution will be used once and not returned to later

The trial evaluated once weekly cagrilintide doses in participants with overweight or obesity and reported dose dependent reductions in body weight at 26 weeks, with the paper describing the treatment as well tolerated in the study setting

London: IntechOpen (2016) 56

Unlike Wegovy injection, Botox does not affect metabolism or appetite

Other Health Conditions Having health issues, including a history of goiter (enlarged thyroid), anemia, or type 1 diabetes, increases your risk for hypothyroidism

Directions on how to use were very clear and I love that